Alzheimer’s drug market faces a $14.7bn future
Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access. For most of its history, treating Alzheimer’s meant donepezil, memantine and a carefully managed decline. Now the money is moving, and quickly. GlobalData expect
<p>Forecast for rapid growth by 2033, with disease-modifying therapies driving sales – and healthcare systems confronting the cost of access. For most of its history, treating Alzheimer’s meant donepezil, memantine and a carefully managed decline. Now the money is moving, and quickly. GlobalData expect</p>